By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: AACC Convention: Takeaways and Industry Updates
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > News > AACC Convention: Takeaways and Industry Updates
News

AACC Convention: Takeaways and Industry Updates

jacquie michels
jacquie michels
Share
4 Min Read
SHARE

Executive vice president David Dolinger,, Ph.D., of a company called Seegene, was good enough to spend some time with me, to explain the firm’s new technology. An official announcement of this diagnostic advance was made today at the AACC show. 

Executive vice president David Dolinger,, Ph.D., of a company called Seegene, was good enough to spend some time with me, to explain the firm’s new technology. An official announcement of this diagnostic advance was made today at the AACC show. 

 
Key about this technology, which Dolinger says will “take molecular diagnostics to the next level,” is that it requires no capital investment. “We are licensing our new technology, which allows symptom-based diagnosis, to other diagnostic firms,” he says. This new technology allows testing for up to 30 targets in one assay. “We’re actually taking medicine from a subjective practice to a science,” said Dolinger. “If you input the correct information, you get actionable information back. With the right markers, you can ask and get the answers to very specific questions. 
 
Rather than using one test per virus, this procedure allows testing for multiple viral enemies with one assay, keeping costs down. “This technology is here, now,” said Dolinger. “We’re not going to hide it when it could change the practice of medicine so substantially. Making it available by license opens this technological door to a broad market. It will potentially make a difference to patients around the world.” Seegene has offices in Maryland, Korea and Germany.
 
The general manager of Arkray, Susumu Akatsu, announced the introduction of a new bench-top analyzer, the Aution II, which can run 450 urinalyses per hour. A fully automated urine analysis system, the AU-4050, which combines urine chemistry and flow cytometry, will be forthcoming from the company next year. The one-station system has what Akatsu calls a “small footprint,” is part of the firm’s push to penetrate US markets. They claim they can standardize systems to fit any size lab.
 
Genisphere has adapted its 3DNA dendrimer signal amplification technology for lateral flow, point-of-care assays, according to Jim Kadushin, vice president and COO, providing improved sensitivity and enabling a broad array of tests at the patient interface. Lateral flow assays represent a unique and growing class of tests designed to quickly diagnose patients for whom time is a key factor.

Genisphere’s 3DNA® signal amplifiers will enable the commercialization of new LF assays that otherwise could not be launched due to unacceptably low sensitivity, and, according to the company, will help labs set themselves apart from a market flooded with products that are limited by both sensitivity and quantitative accuracy.

“Genisphere’s 3DNA® technology provides an improvement of sensitivity in lateral flow assays that no other system has been able to achieve,” said Kadushin.
 
TAGGED:AACC conference
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

Meaningful Use, Secondary Use and Big Data

February 27, 2012

SCOTUS Sets Hearing Dates for ACA Constitutionality; Obama and Romney Weigh Options

November 17, 2011

New Cancer Screening Recommendations Very Controversial

February 14, 2012

Prostate Study Receives Media Attention

April 19, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?